PEPG PepGen Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1835597 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY21.6%
TTM EPS YoY72.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.1%
ROA-46.1%
ROIC (approx.)-121.4%
Asset turnover—
Leverage & solvency
Liabilities / assets19.3%
Debt / equity0.00x
Current ratio8.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $71.04M | $76.48M | $68.13M | $54.08M | $19.00M |
| SG&A expense | $22.57M | $21.26M | $16.64M | $14.22M | $8.11M |
| Operating income | -$93.61M | -$97.74M | -$84.77M | -$68.30M | -$27.11M |
| Pretax income | -$89.61M | -$90.60M | -$78.55M | -$65.40M | -$27.28M |
| Income tax | $48,865 | -$617,000 | $73,000 | $3.70M | $0 |
| Net income | -$89.66M | -$89.98M | -$78.63M | -$69.10M | -$27.28M |
| EBITDA | -$92.21M | -$96.24M | -$83.57M | -$67.80M | -$26.91M |
| EPS (basic) | -2.12 | -2.85 | -3.30 | -4.42 | -30.27 |
| EPS (diluted) | -2.12 | -2.85 | -3.30 | -4.42 | -30.27 |
| Weighted avg. shares (diluted) | 42.22M | 31.58M | 23.80M | 15.64M | 901,108 |
| Balance sheet | |||||
| Cash & equivalents | $60.51M | $49.42M | $80.77M | $181.75M | $132.90M |
| Short-term investments | $87.94M | $70.77M | $29.63M | $0 | — |
| Current assets | $150.96M | $123.76M | $112.68M | $186.08M | $139.99M |
| PP&E, net | $1.90M | $3.72M | $4.76M | $3.33M | $636,000 |
| Total assets | $173.91M | $150.88M | $143.05M | $217.44M | $143.64M |
| Current liabilities | $12.65M | $16.70M | $17.53M | $18.83M | $10.32M |
| Total liabilities | $26.46M | $32.26M | $34.63M | $37.81M | $10.55M |
| Shareholders' equity | $147.44M | $118.62M | $108.42M | $179.63M | -$32.08M |
| Shares outstanding | 68.87M | 32.62M | 23.82M | 23.71M | 963,588 |
| Cash flow statement | |||||
| Operating cash flow | -$81.64M | -$82.37M | -$69.00M | -$59.27M | -$22.60M |
| Capital expenditure | $264,000 | $497,000 | $2.60M | $3.75M | $500,000 |
| Free cash flow | -$81.90M | -$82.87M | -$71.60M | -$63.02M | -$23.10M |
| Investing cash flow | -$15.23M | -$37.67M | -$32.00M | -$3.75M | -$500,000 |
| Financing cash flow | $107.98M | $88.75M | -$189,000 | $112.19M | $147.66M |
| Depreciation & amortization | $1.40M | $1.50M | $1.20M | $500,000 | $200,000 |
| Stock-based compensation | $10.61M | $11.46M | $7.05M | $4.76M | $1.53M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.